Eur J Pharmacol. 2025 Mar 17:177525. doi: 10.1016/j.ejphar.2025.177525. Online ahead of print.
ABSTRACT
Depression is a prevalent and debilitating condition that has a severe negative impact on a person’s life. Chronic stress exposure plays a substantial role in the development of depression. In the present study, rats were exposed to chronic unpredictable mild stress (CUMS) for four weeks. Empagliflozin (EMPA), a Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitor, is an oral antidiabetic agent exhibiting antioxidant, anti-inflammatory, and antiapoptotic effects. This study aimed to examine the antidepressant effect of EMPA in an experimental animal model of depression induced by CUMS in rats and explore the probable underlying mechanisms. Rats were treated with EMPA, per-orally, at a dose of 10 mg/kg/day for four weeks. EMPA treatment counteracted CUMS-induced histopathological, biochemical and behavioral alterations. EMPA suppressed the CUMS-induced increase in the oxidative stress, inflammatory, and apoptotic markers, where levels of MDA, IL-1β, TNF-α, NF-κB, NLRP3 and active caspase 3 were reduced by 29.6%, 24.8%, 17.9%, 36.6%, 24.5% and 41.5%, respectively, compared to the disease group. Furthermore, EMPA decreased the level of the microglial activation marker, iba-1 by 24% in comparison to the disease group. In addition, EMPA treatment decreased blood glucose levels by 39%, decreased serum insulin levels by 60.6%, decreased HOMA-IR by 76.5% and increased GLUT 4 expression, compared to the CUMS group, all which proves that EMPA has an effect insulin signaling and alleviates insulin resistance. Our results conclude that modulating key factors involved in depression, such as inflammation, oxidative stress, and NLRP3 inflammasome pathway, accounts for the anti-depressant effect of EMPA.
PMID:40107336 | DOI:10.1016/j.ejphar.2025.177525
Recent Comments